Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin’s lymphoma: in combination with the International Prognostic Index
- 202 Downloads
The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin’s lymphoma (NHL).
One hundred and thirteen consecutive patients with previously untreated aggressive NHL (diffuse large B-cell lymphoma, 96; peripheral T-cell lymphoma, 17) prospectively participated in this study between 1995 and 2001. The patients were treated with 6–8 cycles of a CHOP or THP (pirarubicin)-COP regimen.
A high serum sIL-2R level (2,000 U/ml and over) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5-year, 24%) than those with low sIL-2R (under 2,000 U/ml) (74%) (P<0.01). Multivariate analysis employing sIL-2R levels and conventional prognostic factors demonstrated that high sIL-2R, presence of B-symptoms, and advanced age (60 years and older) were significantly unfavorable variables for overall survival. In addition, we attempted to use sIL-2R in combination with the International Prognostic Index (IPI). The patients in the high (H) risk group and those with high sIL-2R in the low-intermediate (LI)/high-intermediate (HI) risk group had significantly lower survival rates than the patients in the low (L) risk group and those with low sIL-2R in the LI/HI risk group (P<0.001).
The results suggest that a high serum sIL-2R level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.
KeywordsSoluble interleukin-2 receptor (sIL-2R) International Prognostic Index (IPI) Prognostic factor Non-Hodgkin’s lymphoma
- Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511CrossRefPubMedGoogle Scholar
- Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, Cabanillas F, Kippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an International Workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 17:1244–1253PubMedGoogle Scholar
- Cox DR (1972) Regression models and life-tables (with discussions). J R Stat Soc (Series B) 34:187–220Google Scholar
- Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F for the Group d’Etude des Lymphomes de I’Adulte (1997) Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: updated results of the prospective study LNH87–2. J Clin Oncol 15:1131–1137PubMedGoogle Scholar
- Jaffe ES, Harris NL, Stein H, Vardiman JW, eds (2001) World health organization classification of tumors, pathology and genetics tumors of haematopoietic and lymphoid tissues. IARC, Lyon, 109–236Google Scholar
- Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
- Kitamura K, Takaku F (1990) Pirarubicin, a novel derivative of doxorubicin. THP-COP therapy for non-Hodgkin’s lymphoma in the elderly. Am J Clin Oncol 13 [Suppl 1]:S15-S19Google Scholar
- The non-Hodgkin’s lymphoma pathologic classification project (1982) National Cancer Institute-sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49:2112–2135Google Scholar
- Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T (1996) Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndrome: a relationship with disease subtype and clinical outcome. Brit J Haematol 93:45–52CrossRefGoogle Scholar
- Sawada M, Tsurumi H, Yamada T, Hara T, Fukuno K, Goto H, Shimizu M, Kasahara S, Yoshikawa T, Kanemura N, Oyama M, Takami T, Moriwaki H (2002) A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin’s lymphoma who previously received CHOP therapy as first-line chemotherapy. Eur J Haematol 68:354–361CrossRefPubMedGoogle Scholar
- Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B (1999) International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin’s lymphoma: Report of the July. J Clin Oncol 17:423–429PubMedGoogle Scholar
- Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S (1994) Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin’s lymphoma. Brit J Haematol 88:770–777Google Scholar
- Tsurumi H, Yamada T, Sawada M, Kasahara S, Kanemura N, Kojima Y, Fukuno K, Hara T, Saio M, Takahashi T, Oyama M, Ozawa K, Takami T, Moriwaki H (2004) Biweekly CHOP or biweekly THP-COP regimens in the treatment of aggressive non-Hodgkin’s lymphoma: a comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol 130:107–113CrossRefPubMedGoogle Scholar